Pharmaceutical - Oncology

Filter

Current filters:

Oncology

Popular Filters

126 to 150 of 7121 results

FDA advisory unanimously recommends Durata’s Dalvance

FDA advisory unanimously recommends Durata’s Dalvance

01-04-2014

The US Food and Drug Anti-Infective Drugs Advisory Committee voted 12 to 0 that Durata Therapeutics’…

Antibiotics and Infectious diseasesDalvanceDermatologicalsDurata TherapeuticsNorth AmericaPharmaceuticalRegulationUSA

EMD Serono, Pfizer and Broad Institute link up on lupus research

EMD Serono, Pfizer and Broad Institute link up on lupus research

01-04-2014

EMD Serono, a US subsidiary of Germany’s Merck KGaA, has signed a research agreement with US pharma…

Anti-Arthritics/RheumaticsEMD SeronoMerck KGaAPfizerPharmaceuticalResearch

Paul Sekhri joins Sanofi as Senior Vice President

Paul Sekhri joins Sanofi as Senior Vice President

01-04-2014

Paul Sekhri has joined French drug major Sanofi as Senior Vice President, Integrated Care effective…

BiotechnologyBoardroomPharmaceuticalSanofiUSA

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

01-04-2014

The global pancreatic cancer treatment market value in the six major countries (6MM: the USA, France,…

AbraxaneBiotechnologyCelgeneEuropeMarkets & MarketingOncologyUSA

Janssen files new NDA for combination HIV drug containing darunavir

Janssen files new NDA for combination HIV drug containing darunavir

01-04-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has submitted a New Drug Application…

Anti-viralsDarunavirJanssenPharmaceuticalPrezistaRegulationUSA

Inovio Pharmaceuticals appoints EJ Brandreth as vice president of quality

Inovio Pharmaceuticals appoints EJ Brandreth as vice president of quality

01-04-2014

USA-based Inovio Pharmaceuticals (NYSE MKT: INO) has announced the appointment of EJ Brandreth as Vice…

BoardroomInovio PharmaceuticalsPharmaceuticalUSA

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

01-04-2014

The Pharma Letter interviewed chief executive Dr Thomas Taapken about Epigenomics’ lead product, increasing…

BiotechnologyEpi proColonEpigenomicsGermanyInterviewsOncology

Par Pharmaceutical appoints Terrance Coughlin as chief operating officer

Par Pharmaceutical appoints Terrance Coughlin as chief operating officer

01-04-2014

Par Pharmaceutical Companies (NYSE: PRX) has announced the appointment of Terrance Coughlin as chief…

BoardroomPar PharmaceuticalPar PharmaceuticalsPharmaceuticalUSA

Fairjourney Biologics signs agreement to develop therapeutic antibodies for heparanase

01-04-2014

Portuguese antibody solutions company Fairjourney Biologics has signed a research and option agreement…

BiotechnologyOncologyPortugalResearch

US FTC releases 2013 highlights, including action against Actavis and Mylan

US FTC releases 2013 highlights, including action against Actavis and Mylan

01-04-2014

The US Federal Trade Commission chairwoman Edith Ramirez has released the agency’s 2013 Annual Highlights,…

ActavisMylan LaboratoriesPharmaceuticalRegulationUSA

Otsuka acquires certain Dacogen and E7727 rights from Eisai

01-04-2014

Otsuka Pharmaceutical has reached an agreement with the US subsidiary of fellow Japanese drugmaker Eisai…

DacogenE7727EisaiLicensingOncologyOtsukaPharmaceutical

Lilly's Alimta patent upheld through 2022

Lilly's Alimta patent upheld through 2022

01-04-2014

US pharma major Eli Lilly says that the US District Court for the Southern District of Indiana has ruled…

AlimtaEli LillyLegalNorth AmericaOncologyPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

Price cuts mean PBS can afford new medicines, says Medicines Australia

Price cuts mean PBS can afford new medicines, says Medicines Australia

01-04-2014

As of today in Australia, price cuts come into effect for 121 medicines, and trade group Medicines Australia…

Asia-PacificAustraliaHealthcarePharmaceuticalPricing

Johnson & Johnson accepts $4 billion offer for Ortho-Clinical Diagnostics

Johnson & Johnson accepts $4 billion offer for Ortho-Clinical Diagnostics

01-04-2014

US health care giant Johnson & Johnson revealed yesterday that it has accepted the binding offer from…

Johnson & JohnsonMergers & AcquisitionsPharmaceutical

Lundbeck to enter a partnership with Lieber Institute

Lundbeck to enter a partnership with Lieber Institute

01-04-2014

Danish CNS specialist Lundbeck, together with a number of other companies, is now entering into a collaboration…

LundbeckNeurologicalPharmaceuticalResearch

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

01-04-2014

German drug major Bayer presented new analyses from the pivotal ROCKET AF and EINSTEIN clinical trials…

BayerCardio-vascularJohnson & JohnsonPharmaceuticalResearchXarelto

US Supreme Court agrees to hear Teva’s Copaxone patent appeal

US Supreme Court agrees to hear Teva’s Copaxone patent appeal

01-04-2014

Israel’s Teva Pharmaceutical Industries, the world largest generic drugmaker, says that the US Supreme…

CopaxoneLegalNeurologicalNorth AmericaPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

Bayer’s Adempas gains EU clearance for two forms of PAH

Bayer’s Adempas gains EU clearance for two forms of PAH

31-03-2014

Following a previous positive opinion from the European Medicines Agency’s advisory committee, the…

AdempasBayerEuropePharmaceuticalRegulationRespiratory and Pulmonary

Novartis halts Ph III LCZ696 trial on strong results

Novartis halts Ph III LCZ696 trial on strong results

31-03-2014

Swiss drug major Novartis says that the Data Monitoring Committee (DMC) unanimously recommended early…

Cardio-vascularLCZ696NovartisPharmaceuticalResearch

Jazz Pharma and Gentium debut Defitelio in Europe

31-03-2014

Ireland-headquartered Jazz Pharmaceuticals and its Italian subsidiary Gentium have initiated the European…

AustriaDefitelioEuropeGentiumGermanyJazz PharmaceuticalsMarkets & MarketingPharmaceuticalRare diseases

Bayer Healthcare to invest 100 million euros to expand capacity in China

Bayer Healthcare to invest 100 million euros to expand capacity in China

31-03-2014

The HealthCare division of Germany’s Bayer will invest around 100 million euros ($137.5 million) to…

Asia-PacificBayerChinaFinancialPharmaceuticalProduction

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

31-03-2014

UK pharma major GlaxoSmithKline has withdrawn its application to the European Medicines Agency for a…

GlaxoSmithKlineOncologyPharmaceuticalRegulationUKVotrientWomen's Health

Skyepharma posts 25% revenue growth for 2013

31-03-2014

UK-based Skyepharma, an oral and inhalation drug delivery company, today released financial results for…

FinancialPharmaceuticalSkyepharma

Clinigen gains rights to SpePharm’s Savene

Clinigen gains rights to SpePharm’s Savene

31-03-2014

The UK’s specialty pharma firm Clinigen Group says it has acquired rights to Savene (dexrazoxane) from…

Clinigen GroupGlobalLicensingNorgineOncologyPharmaceuticalSaveneSpePharma

126 to 150 of 7121 results

Back to top